Condition

Urothelial Cancer clinical trials and research

• 23Clinical trials
• 1NIH research projects
• 3New in 30 days
• 27Countries

Newest Urothelial Cancer clinical trials

All recruiting trials (23)

• Dato-DXd in solid tumors (Urothelial Cancer and KRAS-mutant NSCLC) in two sub-studies

  This study tests Datopotamab Deruxtecan (Dato-DXd) alone or with other cancer drugs in people with urothelial cancer or KRAS-mutant non-small cell lung cancer.

  Recruiting Phase 1/2 Daiichi Sankyo · Taichung · NCT07890714

• Peripheral neuropathy during perioperative therapy with enfortumab vedotin and pembrolizumab in muscle-invasive urothelial cancer

  This study follows adults with muscle-invasive urothelial cancer to see how nerve-related side effects develop when people receive enfortumab vedotin and pembrolizumab around surgery as part of standard care.

  Recruiting at 3 sites Comprehensive Cancer Center Munich (CCCM) · Munich, Bavaria and 2 other locations · NCT07870577

• BL-M07D1: T-bren vs standard platinum chemo for HER2-expressing metastatic urothelial cancer after anti-PD-(L)1 therapy

  This trial tests whether T-bren can help people with HER2-expressing metastatic urothelial cancer who progressed after anti-PD-(L)1 therapy, compared with standard platinum-based chemotherapy.

  Recruiting at 2 sites Phase 3 SystImmune Inc. · Macon, Georgia and 1 other locations · NCT07869836

• MGC030 in adults with advanced solid tumors

  This trial tests MGC030 in adults with advanced urothelial, gastric/GEJ, esophageal, colorectal, gastric, pancreatic, or GEJ cancers to see if it is safe and whether it can shrink tumors or stop growth.

  Recruiting Phase 1 MacroGenics · Lake Success, New York · NCT07822399

• Enfortumab vedotin plus pembrolizumab versus chemoradiotherapy for muscle-invasive bladder cancer

  This trial tests whether combining enfortumab vedotin with pembrolizumab can help people with non-metastatic muscle-invasive bladder cancer keep their bladder and control the cancer better than standard concurrent chemoradiotherapy.

  Recruiting at 29 sites Phase 3 Astellas Pharma Inc · Little Rock, Arkansas and 28 other locations · NCT07566156

• Acupuncture and Exercise for EV-Pembro–Induced Peripheral Neuropathy

  This study tests whether adding acupuncture to a gentle virtual exercise program helps reduce chemotherapy-induced nerve problems in bladder cancer patients taking EV and pembrolizumab.

  Recruiting Dana-Farber Cancer Institute · Boston, Massachusetts · NCT07548476

• First-in-human test of CT-202, a nectin-4 directed bispecific antibody for recurrent TNBC, colorectal and urothelial cancers

  This phase 1a/1b study tests CT-202 to see if it is safe and tolerable and to get early signals of activity in patients with nectin-4–expressing recurrent or metastatic TNBC, colorectal cancer, or urothelial cancer who have exhausted standard therapies.

  Recruiting at 6 sites Phase 1 Context Therapeutics Inc. · Wahroonga, New South Wales and 5 other locations · NCT07545122

• PF-08634404 alone or with enfortumab vedotin for advanced urothelial (bladder) cancer

  This trial will try PF-08634404 by itself or together with enfortumab vedotin to see if it is safe and helps adults with advanced or metastatic urothelial (bladder) cancer.

  Recruiting at 173 sites Phase 1/2 Pfizer · Fayetteville, Arkansas and 183 other locations · NCT07421700

• STRO-004 treatment in adults with recurrent or metastatic solid tumors

  This study will test whether STRO-004, alone and with pembrolizumab, is safe and can shrink tumors in adults with several types of metastatic cancers that often express Tissue Factor.

  Recruiting at 9 sites Phase 1 Sutro Biopharma, Inc. · San Diego, California and 8 other locations · NCT07227168

• AVZO-103 alone and with other treatments for advanced urothelial and other solid tumors

  This trial will test intravenous AVZO-103, alone and combined with other cancer drugs, to see if it is safe and helps adults with locally advanced or metastatic urothelial cancer or other solid tumors.

  Recruiting at 15 sites Phase 1/2 Avenzo Therapeutics, Inc. · San Francisco, California and 14 other locations · NCT07193511

• DK222 PET imaging at Johns Hopkins

  This Phase 1 trial will test a PET imaging agent called [18F]DK222 in adults with non-small cell lung cancer or urothelial cancer who are eligible for PD-1/PD-L1 therapy to see if it is safe and how it distributes and how much radiation it gives off.

  Recruiting Phase 1 Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Baltimore, Maryland · NCT07140315

• Datopotamab deruxtecan plus carboplatin or cisplatin versus gemcitabine plus carboplatin or cisplatin for advanced or metastatic urothelial carcinoma

  This trial will test whether datopotamab deruxtecan with carboplatin or cisplatin works better than gemcitabine with carboplatin or cisplatin for people with advanced urothelial carcinoma who progressed during or after enfortumab vedotin plus pembrolizumab.

  Recruiting at 29 sites Phase 2/3 Daiichi Sankyo · Fullerton, California and 99 other locations · NCT07129993

• Izalontamab Brengitecan versus Platinum Chemotherapy for Advanced Urothelial Cancer

  This trial tests whether izalontamab brengitecan works better than standard platinum-based chemotherapy for people with metastatic urothelial (bladder) cancer that progressed after prior immunotherapy.

  Recruiting at 122 sites Phase 2/3 Bristol-Myers Squibb · Gilbert, Arizona and 162 other locations · NCT07106762

• AVZO-1418 alone and with other treatments for advanced epithelial solid tumors

  This trial will test whether intravenous AVZO-1418, alone or with other cancer drugs, is safe and helps adults with locally advanced or metastatic epithelial solid tumors, including some lung cancers.

  Recruiting at 27 sites Phase 1/2 Avenzo Therapeutics, Inc. · Gilbert, Arizona and 26 other locations · NCT07038343

• Sequential gemcitabine plus Jelmyto for favorable high-grade upper tract urothelial cancer

  This trial tests whether giving gemcitabine followed by Jelmyto directly into the kidney can control favorable high‑grade upper tract urothelial cancer and help people avoid kidney removal.

  Recruiting Phase 2 Rutgers, The State University of New Jersey · New Brunswick, New Jersey · NCT06822010

• Investigating nerve damage in patients treated for advanced bladder cancer

  This study is testing how the treatments enfortumab vedotin and pembrolizumab affect nerve damage and quality of life in people with advanced bladder cancer.

  Recruiting at 4 sites Comprehensive Cancer Center Munich (CCCM) · Augsburg, Bavaria and 3 other locations · NCT06657157

• Survey of Adults in South Korea with Urothelial Cancer Receiving PADCEV Injection

  This study looks at how well PADCEV Injection works and its side effects in adults with advanced urothelial cancer in South Korea over 48 weeks.

  Recruiting at 18 sites Astellas Pharma Inc · Goyang-si, Gyeonggi-do and 21 other locations · NCT06011954

• Evaluating Datopotamab Deruxtecan for Advanced Solid Tumours

  This study is testing a new cancer treatment called Datopotamab Deruxtecan to see how well it works and how safe it is for people with advanced solid tumors like ovarian and colorectal cancers.

  Recruiting at 56 sites Phase 2 AstraZeneca · Los Angeles, California and 95 other locations · NCT05489211

• Understanding Urothelial and Rare Genitourinary Cancers

  This study is trying to learn more about urothelial and rare genitourinary cancers by gathering health information and samples from adults who have been diagnosed with these cancers.

  Recruiting National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT04923178

• Sacituzumab govitecan plus enfortumab vedotin for metastatic urothelial cancer

  This trial tests whether combining sacituzumab govitecan and enfortumab vedotin, with pembrolizumab in some patients, helps people with metastatic urothelial carcinoma who have progressed after platinum chemotherapy and PD‑1/PD‑L1 inhibitors.

  Recruiting Phase 1/2 Dana-Farber Cancer Institute · Boston, Massachusetts · NCT04724018

• Combining Anti-PD-1 Therapy with Metformin and Rosiglitazone for Cancer Treatment

  This study is testing if combining a cancer treatment called anti-PD-1 therapy with two diabetes medications, Metformin and Rosiglitazone, can help people with advanced solid tumors fight their cancer better.

  Recruiting Phase 2 University of Pittsburgh · Pittsburgh, Pennsylvania · NCT04114136

• Understanding Urothelial Cancer through Tissue Collection

  This study is collecting tissue and other samples from people with urothelial cancer to see how the disease works and to help find better treatments.

  Recruiting National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT02379429

• Evaluating urine tests for detecting bladder cancer

  This study is testing if urine tests that look for DNA and proteins can help detect bladder and kidney cancers in patients undergoing treatment or with a history of the disease.

  Recruiting Lahey Clinic · Burlington, Massachusetts · NCT00872495

NIH-funded research (1)

Early-stage science funded by the US National Institutes of Health. Most of these projects don't enroll patients, but they show what is being worked on.

• Understanding why some bladder cancer patients respond or resist ADC-immunotherapy combos

  A research project looks at why some bladder cancer patients benefit from antibody-drug conjugate therapy combined with immunotherapy and why others don’t.

  NIH research Sloan-Kettering Inst Can Research · New York, United States · NIH-11335849

Related topics

Quick answers

How many Urothelial Cancer clinical trials are recruiting right now?

23, as of November 12, 2026. 3 of them were first registered in the last 30 days. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 27 countries. The most sites are in United States (18 trials), China (5 trials), Germany (5 trials), Japan (4 trials), Taiwan (3 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 1/2: 5, Phase 1: 4, Phase 2: 3, Phase 3: 2. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →